FCGR3A and COVID-19: Notably, CD8+ T cells from COVID-19 patients showed significantly higher FCGR3A (CD16) expression compared to those from healthy controls (0.31 ± 0.62 vs 0.12 ± 0.43, p=2.47e-08), while no significant difference was observed in CD4+ T cells between the two groups (0.22 ± 0.53 vs 0.34 ± 0.73, p=0.407).